The initial success of Viagra undeniably transformed the pharmaceutical landscape, but investing in companies strongly reliant on unbranded versions presents a complex picture. Despite early returns were significant, the cessation of patents and the emergence of discounted alternatives have weakened the customer base. Therefore, a thorough assessme